DB:74C

Stock Analysis Report

Crossject Société Anonyme

Executive Summary

Crossject Société Anonyme develops needle-free injection systems.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Crossject Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 74C's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.7%

74C

2.6%

DE Medical Equipment

9.1%

DE Market


1 Year Return

-4.0%

74C

10.7%

DE Medical Equipment

-13.1%

DE Market

Return vs Industry: 74C underperformed the German Medical Equipment industry which returned 10.7% over the past year.

Return vs Market: 74C exceeded the German Market which returned -13.1% over the past year.


Shareholder returns

74CIndustryMarket
7 Day-3.7%2.6%9.1%
30 Day11.8%8.7%-1.0%
90 Day-25.3%-10.6%-20.7%
1 Year-4.0%-4.0%12.2%10.7%-10.6%-13.1%
3 Year-63.7%-64.9%110.5%105.6%-10.7%-18.1%
5 Year-75.2%-76.3%238.2%223.7%-10.7%-22.8%

Price Volatility Vs. Market

How volatile is Crossject Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Crossject Société Anonyme undervalued compared to its fair value and its price relative to the market?

15.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 74C's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 74C's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 74C is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: 74C is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 74C's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 74C is overvalued based on its PB Ratio (15.8x) compared to the DE Medical Equipment industry average (4.7x).


Next Steps

Future Growth

How is Crossject Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

13.6%

Forecasted Healthcare industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 74C's forecast earnings growth is above the savings rate (-0.4%).

Earnings vs Market: Insufficient data to determine if 74C's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 74C's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 74C's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 74C's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Crossject Société Anonyme performed over the past 5 years?

-16.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 74C is currently unprofitable.

Growing Profit Margin: 74C is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 74C is unprofitable, and losses have increased over the past 5 years at a rate of -16.7% per year.

Accelerating Growth: Unable to compare 74C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 74C is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17%).


Return on Equity

High ROE: 74C has a negative Return on Equity (-238.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is Crossject Société Anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: 74C's short term assets (€11.8M) exceed its short term liabilities (€5.2M).

Long Term Liabilities: 74C's short term assets (€11.8M) do not cover its long term liabilities (€16.2M).


Debt to Equity History and Analysis

Debt Level: 74C's debt to equity ratio (280.1%) is considered high.

Reducing Debt: Insufficient data to determine if 74C's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 74C has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 74C has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Crossject Société Anonyme's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 74C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 74C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 74C's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 74C's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 74C's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Patrick Alexandre

no data

Tenure

Mr. Patrick Alexandre co-founded Crossject Société Anonyme (f/k/a, Crossject Medical Technology) in 2001 and has been its Chairman of the Executive Board since 2012 and serves as its Chief Executive Office ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 98.4%.


Top Shareholders

Company Information

Crossject Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Crossject Société Anonyme
  • Ticker: 74C
  • Exchange: DB
  • Founded: 1997
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €42.770m
  • Shares outstanding: 24.03m
  • Website: https://www.crossject.com

Number of Employees


Location

  • Crossject Société Anonyme
  • 6 Rue Pauline Kergomard
  • Dijon
  • Burgundy
  • 21000
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALCJENXTPA (Euronext Paris)YesCommon StockFREURFeb 2014
74CDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/10 02:49
End of Day Share Price2020/04/09 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.